Drugs and autoimmunity - A contemporary review and mechanistic approach

Journal of Autoimmunity

Volumn 34, Issue 3, 2010, Pages

  Chang, Christopher ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse drug reactions; Autoantibodies; Autoimmunity; DNA hypomethylation; Drug reactions; Drug induced lupus; Drugs; Immune tolerance; Lupus; Medications; Tolerance; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CEFUROXIME; CIMETIDINE; CLONIDINE; CORTICOSTEROID; DICLOFENAC; DOUBLE STRANDED DNA ANTIBODY; ENALAPRIL; GRISEOFULVIN; HYDRALAZINE; INFLIXIMAB; LEVODOPA; METHYLDOPA; METHYSERGIDE; MINOCYCLINE; PENICILLAMINE; PERAZINE; PRAVASTATIN; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; RESERPINE; SIMVASTATIN; THIORIDAZINE; TIMOLOL; TOLMETIN; UNINDEXED DRUG;

ACNE VULGARIS; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CHROMATIN STRUCTURE; CROHN DISEASE; DERMATOMYOSITIS; DNA METHYLATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CROSS REACTIVITY; ENZYME INHIBITION; HEART ARRHYTHMIA; HUMAN; INCIDENCE; LUPUS LIKE SYNDROME; MACROPHAGE; MEMBRANOUS GLOMERULONEPHRITIS; MYASTHENIA GRAVIS; NONHUMAN; PEMPHIGOID; PEMPHIGUS; POLYMYOSITIS; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; DNA METHYLATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTES; PHARMACEUTICAL PREPARATIONS; SIGNAL TRANSDUCTION;

EID: 77649185475     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.11.012     Document Type: Article

References (101)

1. Shoenfeld Y., Selmi C., Zimlichman E., and Gershwin M.E. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31 (2008) 325-330
2. Vedove C.D., Del Giglio M., Schena D., and Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 301 (2009) 99-105
3. Cannat A., and Seligmann M. Induction by isoniazid and hydrallazine of antinuclear factors in mice. Clin Exp Immunol 3 (1968) 99-105
4. Burlingame R.W., and Rubin R.L. Autoantibody to the nucleosome subunit (H2A-H2B)-DNA is an early and ubiquitous feature of lupus-like conditions. Mol Biol Rep 23 (1996) 159-166
5. Pugh S., Pelton B., Raftery E.B., and Denman A.M. Abnormal lymphocyte function is secondary to drug-induced autoimmunity. Ann Rheum Dis 35 (1976) 344-348
6. Mongey A.B., Donovan-Brand R., Thomas T.J., Adams L.E., and Hess E.V. Serologic evaluation of patients receiving procainamide. Arthritis Rheum 35 (1992) 219-223
7. Rubin R.L., and Kretz-Rommel A. Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus. Environ Health Perspect 107 Suppl. 5 (1999) 803-806
8. Kretz-Rommel A., Duncan S.R., and Rubin R.L. Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus. J Clin Invest 99 (1997) 1888-1896
9. Pichler W.J. Drug-induced autoimmunity. Curr Opin Allergy Clin Immunol 3 (2003) 249-253
10. Kretz-Rommel A., and Rubin R.L. Disruption of positive selection of thymocytes causes autoimmunity. Nat Med 6 (2000) 298-305
11. Quddus J., Johnson K.J., Gavalchin J., Amento E.P., Chrisp C.E., Yung R.L., et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92 (1993) 38-53
12. Zhou Y., and Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev 7 (2008) 376-383
13. Scheinbart L.S., Johnson M.A., Gross L.A., Edelstein S.R., and Richardson B.C. Procainamide inhibits DNA methyltransferase in a human T cell line. J Rheumatol 18 (1991) 530-534
14. Gorelik G., and Richardson B. Aberrant T cell ERK pathway signaling and chromatin structure in lupus. Autoimmun Rev 8 (2009) 196-198
15. Deng C., Lu Q., Zhang Z., Rao T., Attwood J., Yung R., et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 48 (2003) 746-756
16. Gorelik G., Fang J.Y., Wu A., Sawalha A.H., and Richardson B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol 179 (2007) 5553-5563
17. Rao T., and Richardson B. Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 107 Suppl. 5 (1999) 737-742
18. Berger N.A., Whitacre C.M., Hashimoto H., Berger S.J., and Chatterjee S. NAD and poly(ADP-ribose) regulation of proteins involved in response to cellular stress and DNA damage. Biochimie 77 (1995) 364-367
19. Lee J.S., Haug B.L., and Sibley J.T. Decreased mRNA levels coding for poly(ADP-ribose) polymerase in lymphocytes of patients with SLE. Lupus 3 (1994) 113-116
20. Yung R., Powers D., Johnson K., Amento E., Carr D., Laing T., et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupus like disease in syngeneic mice. J Clin Invest 97 (1996) 2866-2871
21. Lu Q., Kaplan M., Ray D., Zacharek S., Gutsch D., and Richardson B. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 1282-1291
22. Lu Q., Wu A., and Richardson B.C. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 174 (2005) 6212-6219
23. Kaplan M.J., Lu Q., Wu A., Attwood J., and Richardson B. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J Immunol 172 (2004) 3652-3661
24. Matsuura T., Shimizu Y., Fujimoto H., Miyazaki T., and Kano S. Minocycline-related lupus. Lancet 340 (1992) 1553
25. Goldstein N.S., Bayati N., Silverman A.L., and Gordon S.C. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 114 (2000) 591-598
26. Angulo J.M., Sigal L.H., and Espinoza L.R. Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Semin Arthritis Rheum 28 (1998) 187-192
27. Lawson T.M., Amos N., Bulgen D., and Williams B.D. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 40 (2001) 329-335
28. Dunphy J., Oliver M., Rands A.L., Lovell C.R., and McHugh N.J. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 142 (2000) 461-467
29. Li J., and Uetrecht J.P. d-Penicillamine-induced autoimmunity: relationship to macrophage activation. Chem Res Toxicol (2009)
30. Masson M.J., Teranishi M., Shenton J.M., and Uetrecht J.P. Investigation of the involvement of macrophages and T cells in d-penicillamine-induced autoimmunity in the brown Norway rat. J Immunotoxicol 1 (2004) 79-93
31. O'Brien B.A., Archer N.S., Simpson A.M., Torpy F.R., and Nassif N.T. Association of SLC11A1 promoter polymorphisms with the incidence of autoimmune and inflammatory diseases: a meta-analysis. J Autoimmun 31 (2008) 42-51
32. Ramos-Casals M., Roberto Perez A., Diaz-Lagares C., Cuadrado M.J., and Khamashta M.A. Autoimmune diseases induced by biological agents a double-edged sword?. Autoimmun Rev (2009)
33. Valesini G., Iannuccelli C., Marocchi E., Pascoli L., Scalzi V., and Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 7 (2007) 35-41
34. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., and Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43 (2000) 2383-2390
35. Vermeire S., Noman M., Van Assche G., Baert F., Van Steen K., Esters N., et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125 (2003) 32-39
36. Jonsdottir T., Forslid J., van Vollenhoven A., Harju A., Brannemark S., Klareskog L., et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63 (2004) 1075-1078
37. Elkayam O., Burke M., Vardinon N., Zakut V., Yitzhak R.B., Paran D., et al. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 38 (2005) 155-160
38. Mohan N., Edwards E.T., Cupps T.R., Slifman N., Lee J.H., Siegel J.N., et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31 (2004) 1955-1958
39. Costa M.F., Said N.R., and Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37 (2008) 381-387
40. Shakoor N., Michalska M., Harris C.A., and Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 (2002) 579-580
41. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86 (2007) 242-251
42. De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus 15 (2006) 762-767
43. Mackay I.R., Leskovsek N.V., and Rose N.R. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 30 (2008) 5-11
44. Lleo A., Selmi C., Invernizzi P., Podda M., and Gershwin M.E. The consequences of apoptosis in autoimmunity. J Autoimmun 31 (2008) 257-262
45. van Steensel M.A. Why minocycline can cause systemic lupus - a hypothesis and suggestions for therapeutic interventions based on it. Med Hypotheses 63 (2004) 31-34
46. Raychaudhuri S.P., Nguyen C.T., Raychaudhuri S.K., and Gershwin M.E. Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev 9 (2009) 67-81
47. Pordeus V., Szyper-Kravitz M., Levy R.A., Vaz N.M., and Shoenfeld Y. Infections and autoimmunity: a panorama. Clin Rev Allergy Immunol 34 (2008) 283-299
48. Amital H., Govoni M., Maya R., Meroni P.L., Ori B., Shoenfeld Y., et al. Role of infectious agents in systemic rheumatic diseases. Clin Exp Rheumatol 26 (2008) S27-S32
49. Burek C.L., and Talor M.V. Environmental triggers of autoimmune thyroiditis. J Autoimmun (2009)
50. Wasserman E.E., Nelson K., Rose N.R., Rhode C., Pillion J.P., Seaberg E., et al. Infection and thyroid autoimmunity: a seroepidemiologic study of TPOaAb. Autoimmunity 42 (2009) 439-446
51. Ferraccioli G., Mecchia F., Di Poi E., and Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 61 (2002) 358-361
52. Ishimaru N., Takagi A., Kohashi M., Yamada A., Arakaki R., Kanno J., et al. Neonatal exposure to low-dose 2,3,7,8-tetrachlorodibenzo-p-dioxin causes autoimmunity due to the disruption of T cell tolerance. J Immunol 182 (2009) 6576-6586
53. Atkins M.B., Mier J.W., Parkinson D.R., Gould J.A., Berkman E.M., and Kaplan M.M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318 (1988) 1557-1563
54. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 (2006) 709-718
55. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100 (2003) 8372-8377
56. Ronnblom L.E., Alm G.V., and Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115 (1991) 178-183
57. Conlon K.C., Urba W.J., Smith II J.W., Steis R.G., Longo D.L., and Clark J.W. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65 (1990) 2237-2242
58. Cohen M.G., Kevat S., Prowse M.V., and Ahern M.J. Two distinct quinidine-induced rheumatic syndromes. Ann Intern Med 108 (1988) 369-371
59. Clauser S., Fischer A.M., and Darnige L. Quinidine-induced lupus anticoagulant, hypoprothrombinemia, and antiprothrombin antibodies. Am J Hematol 82 (2007) 330
60. Ablin J., Verbovetski I., Trahtemberg U., Metzger S., and Mevorach D. Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: a novel contributing mechanism of drug-induced-lupus. Apoptosis 10 (2005) 1009-1018
61. Baumann I., Kolowos W., Voll R.E., Manger B., Gaipl U., Neuhuber W.L., et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 46 (2002) 191-201
62. Bray V.J., West S.G., Schultz K.T., Boumpas D.T., and Rubin R.L. Antihistone antibody profile in sulfasalazine induced lupus. J Rheumatol 21 (1994) 2157-2158
63. Gunnarsson I., Nordmark B., Hassan Bakri A., Grondal G., Larsson P., Forslid J., et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford) 39 (2000) 886-893
64. Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21 (2007) 17-24
65. Chapman-Shimshoni D., Yuklea M., Radnay J., Shapiro H., and Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 31 (2003) 779-783
66. Millard T.P., Hawk J.L., and McGregor J.M. Photosensitivity in lupus. Lupus 9 (2000) 3-10
67. Caricchio R., McPhie L., and Cohen P.L. Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol 171 (2003) 5778-5786
68. Ehrenstein M.R., Jury E.C., and Mauri C. Statins for atherosclerosis - as good as it gets?. N Engl J Med 352 (2005) 73-75
69. Hieronymus T., Grotsch P., Blank N., Grunke M., Capraru D., Geiler T., et al. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus?. Arthritis Rheum 43 (2000) 1994-2004
70. Damoiseaux J.G., Beijleveld L.J., and van Breda Vriesman P.J. Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. Clin Immunol Immunopathol 82 (1997) 197-202
71. Moraes-Fontes M.F., Rebelo M., Caramalho I., Zelenay S., Bergman M.L., Coutinho A., et al. Steroid treatments in mice do not alter the number and function of regulatory T cells, but amplify cyclophosphamide-induced autoimmune disease. J Autoimmun 33 (2009) 109-120
72. Surveyor I., Evans B., Saunders K.C., and Parry T.E. Autoimmune haemolytic anaemia complicating methyldopa therapy. Postgrad Med J 44 (1968) 438-442
73. Saif M.W., The A., and Ledbetter L. Oxaliplatin-mediated autoimmune thrombocytopenia. Clin Colorectal Cancer 8 (2009) 61-62
74. Sen K., and Kalaycio M. Evan's syndrome precipitated by fludarabine therapy in a case of CLL. Am J Hematol 61 (1999) 219
75. de Quiros J.F., Pinto V., Hevia S., and Vigon R. Immune complex-mediated haemolytic anaemia and Evans syndrome induced by diclofenac. Vox Sang 72 (1997) 121-123
76. Keung Y.K., Mallarino M.C., and Cobos E. Drug-induced Evans syndrome. Ann Intern Med 128 (1998) 327
77. Bagenstose L.M., Salgame P., and Monestier M. Murine mercury-induced autoimmunity: a model of chemically related autoimmunity in humans. Immunol Res 20 (1999) 67-78
78. Martinsson K., Carlsson L., Kleinau S., and Hultman P. The effect of activating and inhibiting Fc-receptors on murine mercury-induced autoimmunity. J Autoimmun 31 (2008) 22-29
79. Yoshida S., and Gershwin M.E. Autoimmunity and selected environmental factors of disease induction. Semin Arthritis Rheum 22 (1993) 399-419
80. Kahaly G.J., Dienes H.P., Beyer J., and Hommel G. Iodide induces thyroid autoimmunity in patients with endemic goitre: a randomised, double-blind, placebo-controlled trial. Eur J Endocrinol 139 (1998) 290-297
81. Veltman G., Lange C.E., Juhe S., Stein G., and Bachner U. Clinical manifestations and course of vinyl chloride disease. Ann N Y Acad Sci 246 (1975) 6-17
82. Montanaro A., and Bardana Jr. E.J. Dietary amino acid-induced systemic lupus erythematosus. Rheum Dis Clin North Am 17 (1991) 323-332
83. Nietert P.J., Sutherland S.E., Silver R.M., Pandey J.P., Knapp R.G., Hoel D.G., et al. Is occupational organic solvent exposure a risk factor for scleroderma?. Arthritis Rheum 41 (1998) 1111-1118
84. Bell S.A., Hobbs M.V., and Rubin R.L. Isotype-restricted hyperimmunity in a murine model of the toxic oil syndrome. J Immunol 148 (1992) 3369-3376
85. Wilke R.A., Salisbury S., Abdel-Rahman E., and Brazy P.C. Lupus-like autoimmune disease associated with silicosis. Nephrol Dial Transplant 11 (1996) 1835-1838
86. Zwick H., Popp W., Wagner C., Reiser K., Schmoger J., Bock A., et al. Effects of ozone on the respiratory health, allergic sensitization, and cellular immune system in children. Am Rev Respir Dis 144 (1991) 1075-1079
87. Deeg H.J. Ultraviolet irradiation in transplantation biology. Manipulation of immunity and immunogenicity. Transplantation 45 (1988) 845-851
88. Powell J.J., Van de Water J., and Gershwin M.E. Evidence for the role of environmental agents in the initiation or progression of autoimmune conditions. Environ Health Perspect 107 Suppl. 5 (1999) 667-672
89. Nancy A.L., and Shoenfeld Y. Chronic fatigue syndrome with autoantibodies-the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 8 (2008) 52-55
90. Iskander J., and Broder K. Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience. Expert Rev Vaccines 7 (2008) 75-82
91. Invernizzi P., Pasini S., Selmi C., Miozzo M., and Podda M. Skewing of X chromosome inactivation in autoimmunity. Autoimmunity 41 (2008) 272-277
92. Lleo A., Battezzati P.M., Selmi C., Gershwin M.E., and Podda M. Is autoimmunity a matter of sex?. Autoimmun Rev 7 (2008) 626-630
93. Cooper G.S., Bynum M.L., and Somers E.C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun (2009)
94. Shoenfeld Y., Gilburd B., Abu-Shakra M., Amital H., Barzilai O., Berkun Y., et al. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases - 2008. Isr Med Assoc J 10 (2008) 3-7
95. Invernizzi P. Future directions in genetic for autoimmune diseases. J Autoimmun 33 (2009) 1-2
96. Doria A., Sarzi-Puttini P., and Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev 8 (2008) 1-4
97. Shoenfeld Y., Blank M., Abu-Shakra M., Amital H., Barzilai O., Berkun Y., et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases - 2008. Isr Med Assoc J 10 (2008) 13-19
98. Shoenfeld Y., Zandman-Goddard G., Stojanovich L., Cutolo M., Amital H., Levy Y., et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases - 2008. Isr Med Assoc J 10 (2008) 8-12
99. Pauley K.M., Cha S., and Chan E.K. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 32 (2009) 189-194
100. Carissimi C., Fulci V., and Macino G. MicroRNAs: novel regulators of immunity. Autoimmun Rev 8 (2009) 520-524
101. Laroche M., Borg S., Lassoued S., De Lafontan B., and Roche H. Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. J Rheumatol 34 (2007) 2259-2263